Clinical Trial Update: An Observational Study of Tarceva (Erlotinib) in Routine Daily Clinical Practice as Second Line Treatment in Patients With Non-small Cell Lung Cancer

View source ↗

Summary

An observational study evaluating Tarceva (erlotinib) as second-line treatment for non-small cell lung cancer in routine daily clinical practice; the trial is c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tarceva (erlotinib)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Nonsquamous Nonsmall Cell Neoplasm of Lung | Status: COMPLETED | Results posted: 2016-03-28